Abstract
Case:Duchenne/Becker muscular dystrophy (DMD/BeMD) is caused by a loss of dystrophin leading to muscular weakness. Glucocorticoids are used to delay loss of muscle strength but frequently result in osteoporosis and fractures. Bisphosphonates are the drug of choice, and there are limited data on the efficacy of denosumab. We describe 2 patients who were treated with denosumab and had stable to improved bone density with no side effects.Conclusion:Denosumab can be considered for the treatment of osteoporosis in adults with DMD/BeMD, especially when the response to bisphosphonates is not satisfactory.
Author supplied keywords
Cite
CITATION STYLE
Hung, C., Mathews, K. D., & Shibli-Rahhal, A. (2022). Effect of Denosumab on Bone Health in Adult Patients with Duchenne/Becker Muscular Dystrophy: A Report of 2 Cases. JBJS Case Connector, 12(1). https://doi.org/10.2106/JBJS.CC.21.00664
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.